Listen in as Cristina Mussini, MD; Martin Witzenrath, MD, FERS; and Michele Bartoletti, MD, PhD, discuss best practices in managing people who are immunocompromised with COVID-19 in the hospital setting, including:

• COVID-19 burden among this population
• Initial workup to assess disease severity
• Summary of COVID-19 guideline recommendations
• A detailed patient case to illustrate key takeaways

Presenters:

Michele Bartoletti, MD, PhD​
Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy

Cristina Mussini, MD​
Full Professor of Infectious Diseases
Chief of the Department of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Martin Witzenrath, MD, FERS
Medical Director
Charite Centrum 12
Internal Medicine & Dermatology
Professor and Chair for Respiratory Medicine and Critical Care
Department of Infectious Disease, Respiratory Medicine and Critical Care
Charite Campus Mitte/Campus Virchow Klinikum/Campus Benamin Franklin
Charite – University of Berlin
Berlin, Germany

Link to full program:
https://bit.ly/4fs7Hcb

Downloadable slides:
https://bit.ly/4imCRU5

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Dr Robert Cotes and Dr David Goldsmith discuss their clinical experience with long-acting injectable antipsychotic treatments in the Grady Health System, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making.

Presenters:

Robert O. Cotes, MD, DFAPA
Associate Professor and Distinguished Physician
Director, Clinical & Research Program for Psychosis at Grady Health System
Director, Project ARROW at Grady Health System
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

David R. Goldsmith, MD, MSc
Associate Professor
Director, Inflammation, Motivation, and Negative Symptoms of Schizophrenia (InMotioNSS) Lab
Co-Director, Clinical & Research Program for Psychosis at Grady Health System
Director, PSTAR Clinic at Grady Memorial Hospital
Faculty, Emory Behavioral Immunology Program
Co-Director, Psychiatry Residency Research Track
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

This content is part of an online CME program supported by educational grants from Indivior Inc.; Otsuka America Pharmaceutical, Inc. and Lundbeck; and Teva Pharmaceuticals.

Link to full program: https://bit.ly/414XkY4

In this episode, David N. Lieberman, MD, PhD, and Eric Marsh, MD, PhD, discuss recent updates relevant to the treatment of Rett syndrome, including:

• The recently updated Comprehensive Care Guidelines from the International Rett Syndrome Foundation, available at rettsyndrome.org
• Ongoing collection and analysis of longitudinal data within the Rett Syndrome Natural History Study
• Efficacy and safety data from the double-blind, placebo-controlled phase III registrational LAVENDER trial evaluating oral trofinetide, a small molecule analogue of insulin-like growth factor 1
• Topline results from phase III AVATAR and EXCELLENCE trials of the sigma-1 receptor agonist blarcamesine
• Several early ongoing gene therapy trials

Dr Lieberman and Dr Marsh complement this informative update with wisdom from their own clinical experience to provide a full picture of current treatment and management options available to patients with Rett syndrome.

Presenters:

David N. Lieberman, MD, PhD
Director, Comprehensive Rett Syndrome Clinic
Department of Neurology
Boston Children's Hospital
Boston, Massachusetts

Eric Marsh, MD PhD
Clinical Director, Orphan Disease Center
Director (MPI), CHOP/Penn IDDRC
Professor, Departments of Neurology and Pediatrics
Division of Neurology
Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

This content is part of an online CME program in partnership with the International Rett Syndrome Foundation and supported by an educational grant from Acadia Pharmaceuticals. Link to full program:
https://bit.ly/4fJRRL0